Literature DB >> 23940047

Nicotinamide adenine dinucleotide-induced multimerization of the co-repressor CtBP1 relies on a switching tryptophan.

Dana L Madison1, Jacqueline A Wirz, Don Siess, James R Lundblad.   

Abstract

The transcriptional co-repressor C-terminal binding protein (CtBP) interacts with a number of repressor proteins and chromatin modifying enzymes. How the biochemical properties including binding of dinucleotide, oligomerization, and dehydrogenase domains of CtBP1 direct the assembly of a functional co-repressor to influence gene expression is not well understood. In the current study we demonstrate that CtBP1 assembles into a tetramer in a NAD(H)-dependent manner, proceeding through a dimeric intermediate. We find that NAD-dependent oligomerization correlates with NAD(+) binding affinity and that the carboxyl terminus is required for assembly of a dimer of dimers. Mutant CtBP1 proteins that abrogate dinucleotide-binding retain wild type affinity for the PXDLS motif, but do not self-associate either in vitro or in vivo. CtBP1 proteins with mutations in the dehydrogenase domain still retain the ability to self-associate and bind target proteins. Both co-immunoprecipitation and mammalian two-hybrid experiments demonstrate that CtBP1 self-association occurs within the nucleus, and depends on dinucleotide binding. Repression of transcription does not depend on dinucleotide binding or an intact dehydrogenase domain, but rather depends on the amino-terminal domain that recruits PXDLS containing targets. We show that tryptophan 318 (Trp(318)) is a critical residue for tetramer assembly and likely functions as a switch for effective dimerization following NAD(+) binding. These results suggest that dinucleotide binding permits CtBP1 to form an intranuclear homodimer through a Trp(318) switch, creating a nucleation site for multimerization through the C-terminal domain for tetramerization to form an effective repression complex.

Entities:  

Keywords:  C-terminal-binding Protein; Corepressor Transcription; Dehydrogenase; NAD; Protein-Protein Interactions; Transcription

Mesh:

Substances:

Year:  2013        PMID: 23940047      PMCID: PMC3784699          DOI: 10.1074/jbc.M113.493569

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Transcription corepressor CtBP is an NAD(+)-regulated dehydrogenase.

Authors:  Vivek Kumar; Justin E Carlson; Kenneth A Ohgi; Thomas A Edwards; David W Rose; Carlos R Escalante; Michael G Rosenfeld; Aneel K Aggarwal
Journal:  Mol Cell       Date:  2002-10       Impact factor: 17.970

2.  Regulation of corepressor function by nuclear NADH.

Authors:  Qinghong Zhang; David W Piston; Richard H Goodman
Journal:  Science       Date:  2002-02-14       Impact factor: 47.728

3.  Removal of the tryptophan 139 side chain in Escherichia coli D-3-phosphoglycerate dehydrogenase produces a dimeric enzyme without cooperative effects.

Authors:  G A Grant; X L Xu; Z Hu
Journal:  Arch Biochem Biophys       Date:  2000-03-01       Impact factor: 4.013

4.  C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs.

Authors:  Madeleine Grooteclaes; Quinn Deveraux; Jeffrey Hildebrand; Qinghong Zhang; Richard H Goodman; Steven M Frisch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

Review 5.  CtBP, an unconventional transcriptional corepressor in development and oncogenesis.

Authors:  G Chinnadurai
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

6.  Nicotinamide adenine dinucleotide stimulates oligomerization, interaction with adenovirus E1A and an intrinsic dehydrogenase activity of CtBP.

Authors:  P Balasubramanian; Ling Jun Zhao; G Chinnadurai
Journal:  FEBS Lett       Date:  2003-02-27       Impact factor: 4.124

7.  Acetylation of the adenovirus-transforming protein E1A determines nuclear localization by disrupting association with importin-alpha.

Authors:  Dana L Madison; Peter Yaciuk; Roland P S Kwok; James R Lundblad
Journal:  J Biol Chem       Date:  2002-08-02       Impact factor: 5.157

8.  Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development.

Authors:  Jeffrey D Hildebrand; Philippe Soriano
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

9.  Cofactor binding to Escherichia coli D-3-phosphoglycerate dehydrogenase induces multiple conformations which alter effector binding.

Authors:  Gregory A Grant; Zhiqin Hu; Xiao Lan Xu
Journal:  J Biol Chem       Date:  2002-08-14       Impact factor: 5.157

10.  Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.

Authors:  Li-Jun Di; Jung S Byun; Madeline M Wong; Clay Wakano; Tara Taylor; Sven Bilke; Songjoon Baek; Kent Hunter; Howard Yang; Maxwell Lee; Cecilia Zvosec; Galina Khramtsova; Fan Cheng; Charles M Perou; C Ryan Miller; Rachel Raab; Olufunmilayo I Olopade; Kevin Gardner
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  15 in total

1.  Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.

Authors:  Brendan J Hilbert; Steven R Grossman; Celia A Schiffer; William E Royer
Journal:  FEBS Lett       Date:  2014-03-19       Impact factor: 4.124

2.  Assembly of human C-terminal binding protein (CtBP) into tetramers.

Authors:  Andrew G Bellesis; Anne M Jecrois; Janelle A Hayes; Celia A Schiffer; William E Royer
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

3.  A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity.

Authors:  David B Beck; T Subramanian; S Vijayalingam; Uthayashankar R Ezekiel; Sandra Donkervoort; Michele L Yang; Holly A Dubbs; Xilma R Ortiz-Gonzalez; Shenela Lakhani; Devorah Segal; Margaret Au; John M Graham; Sumit Verma; Darrel Waggoner; Marwan Shinawi; Carsten G Bönnemann; Wendy K Chung; G Chinnadurai
Journal:  Neurogenetics       Date:  2019-04-30       Impact factor: 2.660

4.  Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.

Authors:  M Michael Dcona; Priyadarshan K Damle; Francisco Zarate-Perez; Benjamin L Morris; Zaid Nawaz; Michael J Dennis; Xiaoyan Deng; Sudha Korwar; Sahib J Singh; Keith C Ellis; William E Royer; Dipankar Bandyopadhyay; Carlos Escalante; Steven R Grossman
Journal:  Mol Pharmacol       Date:  2019-04-29       Impact factor: 4.436

5.  NAD+ promotes assembly of the active tetramer of aldehyde dehydrogenase 7A1.

Authors:  David A Korasick; Tommi A White; Srinivas Chakravarthy; John J Tanner
Journal:  FEBS Lett       Date:  2018-09-18       Impact factor: 4.124

6.  Tête-à-tête with CtBP dimers.

Authors:  Ana-Maria Raicu; Kalynn M Bird; David N Arnosti
Journal:  Structure       Date:  2021-04-01       Impact factor: 5.006

7.  Cryo-EM structure of CtBP2 confirms tetrameric architecture.

Authors:  Anne M Jecrois; M Michael Dcona; Xiaoyan Deng; Dipankar Bandyopadhyay; Steven R Grossman; Celia A Schiffer; William E Royer
Journal:  Structure       Date:  2020-12-01       Impact factor: 5.871

Review 8.  CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors.

Authors:  M Michael Dcona; Benjamin L Morris; Keith C Ellis; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2017-05-22       Impact factor: 4.742

9.  ANGUSTIFOLIA, a Plant Homolog of CtBP/BARS Localizes to Stress Granules and Regulates Their Formation.

Authors:  Hemal Bhasin; Martin Hülskamp
Journal:  Front Plant Sci       Date:  2017-06-13       Impact factor: 5.753

10.  Inhibition of CtBP-Regulated Proinflammatory Gene Transcription Attenuates Psoriatic Skin Inflammation.

Authors:  Hong Li; Caiguo Zhang; Li Bian; Hui Deng; Melanie Blevins; Gangwen Han; Bin Fan; Chunxia Yang; Rui Zhao; Whitney High; David Norris; Mayumi Fujita; Xiao-Jing Wang; Mingxia Huang
Journal:  J Invest Dermatol       Date:  2021-07-20       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.